Mo:re

Executive Summary

Mo:re is a German biotechnology company headquartered in Munich, founded in 2018, that addresses a critical bottleneck in preclinical drug development: the manual, labor-intensive process of 3D cell culture. Their integrated lab platform automates and standardizes the entire workflow—from planning and preparation to execution and AI-assisted analysis—enabling the generation of high-quality, reproducible organoid and spheroid models. By reducing human error and increasing throughput, Mo:re enhances the predictability of drug responses and disease modeling, aiming to bridge the gap between promising 3D models and clinical translation. The platform targets the growing demand for advanced in vitro models in drug discovery, personalized medicine, and toxicology, appealing to pharmaceutical companies, CROs, and academic researchers. With a focus on scalability and data standardization, Mo:re positions itself as an enabler of more efficient and reliable preclinical assays, potentially reducing reliance on animal testing and accelerating the development of new therapies. Despite the clear market need and an innovative solution, Mo:re operates in a competitive landscape that includes both established players (e.g., Corning, Thermo Fisher) and emerging startups. The company's success hinges on its ability to secure partnerships with key pharma players, demonstrate superior performance in head-to-head trials, and navigate the complex regulatory environment for digital health and lab automation tools. With a relatively early stage (no disclosed funding or revenue), execution risk remains. The key catalysts to watch include potential Series A funding, strategic partnerships, and product validation at industry conferences. Overall, Mo:re presents a compelling opportunity in the digital health and AI-driven drug delivery space, but conviction is tempered by the early-stage nature and competitive dynamics.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Announcement70% success
• Q4 2026Strategic Partnership with Major Pharma50% success
• Q1 2027Product Launch at SLAS 202780% success